ChemoCentryx, Inc. (CCXI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
36.28-2.60 (-6.69%)
At close: 1:00PM EST
38.49 +2.21 (+6.09%)
After hours: 04:55PM EST
After hours: 04:55PM EST
Currency in USD
Valuation Measures
| Market Cap (intraday) 5 | 2.74B |
| Enterprise Value 3 | 2.55B |
| Trailing P/E | N/A |
| Forward P/E 1 | N/A |
| PEG Ratio (5 yr expected) 1 | N/A |
| Price/Sales (ttm) | 80.65 |
| Price/Book (mrq) | 8.69 |
| Enterprise Value/Revenue 3 | 75.30 |
| Enterprise Value/EBITDA 7 | -22.00 |
Trading Information
Stock Price History
| Beta (5Y Monthly) | 1.83 |
| 52-Week Change 3 | -29.50% |
| S&P500 52-Week Change 3 | 29.82% |
| 52 Week High 3 | 70.29 |
| 52 Week Low 3 | 9.53 |
| 50-Day Moving Average 3 | 31.05 |
| 200-Day Moving Average 3 | 29.58 |
Share Statistics
| Avg Vol (3 month) 3 | 4.97M |
| Avg Vol (10 day) 3 | 1.32M |
| Shares Outstanding 5 | 70.03M |
| Implied Shares Outstanding 6 | N/A |
| Float 8 | 57.76M |
| % Held by Insiders 1 | 17.57% |
| % Held by Institutions 1 | 64.14% |
| Shares Short (Nov. 14, 2021) 4 | 6.04M |
| Short Ratio (Nov. 14, 2021) 4 | 3.36 |
| Short % of Float (Nov. 14, 2021) 4 | 12.75% |
| Short % of Shares Outstanding (Nov. 14, 2021) 4 | 8.63% |
| Shares Short (prior month Oct. 14, 2021) 4 | 5.48M |
Dividends & Splits
| Forward Annual Dividend Rate 4 | N/A |
| Forward Annual Dividend Yield 4 | N/A |
| Trailing Annual Dividend Rate 3 | N/A |
| Trailing Annual Dividend Yield 3 | N/A |
| 5 Year Average Dividend Yield 4 | N/A |
| Payout Ratio 4 | 0.00% |
| Dividend Date 3 | N/A |
| Ex-Dividend Date 4 | N/A |
| Last Split Factor 2 | N/A |
| Last Split Date 3 | N/A |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | Dec. 30, 2020 |
| Most Recent Quarter (mrq) | Sep. 29, 2021 |
Profitability
| Profit Margin | 0.00% |
| Operating Margin (ttm) | -348.58% |
Management Effectiveness
| Return on Assets (ttm) | -15.11% |
| Return on Equity (ttm) | -33.61% |
Income Statement
| Revenue (ttm) | 34.27M |
| Revenue Per Share (ttm) | 0.49 |
| Quarterly Revenue Growth (yoy) | 248.90% |
| Gross Profit (ttm) | -12.99M |
| EBITDA | -116.93M |
| Net Income Avi to Common (ttm) | -121.1M |
| Diluted EPS (ttm) | -1.74 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 269.43M |
| Total Cash Per Share (mrq) | 3.85 |
| Total Debt (mrq) | 72.95M |
| Total Debt/Equity (mrq) | 23.09 |
| Current Ratio (mrq) | 4.89 |
| Book Value Per Share (mrq) | 4.52 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -83.96M |
| Levered Free Cash Flow (ttm) | -91.6M |
